| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
DSPE-PEG 2000 does not have a specific biological target. Its primary function is as a formulation excipient for drug delivery systems. The DSPE component integrates into lipid bilayers, while the PEG chain provides a hydrophilic "stealth" coating that reduces immune recognition and prolongs circulation time. This improves the pharmacokinetics and biodistribution of encapsulated drugs.
|
|---|---|
| ln Vitro |
In vitro, DSPE-PEG 2000 is used to formulate liposomes and nanoparticles for drug delivery. Its presence in formulations has been shown to reduce uptake by macrophages and increase stability in biological fluids. Specific activity data, such as IC50 values, are not applicable as it is not a pharmacologically active drug.
|
| ln Vivo |
In vivo, DSPE-PEG 2000 is used to formulate liposomal drug delivery systems with extended circulation times. PEGylated liposomes have been shown to have reduced clearance by the reticuloendothelial system and increased accumulation in target tissues. The compound has been used to form stable micelles for drug delivery, enhancing the therapeutic index of encapsulated drugs.
|
| Enzyme Assay |
A cell-free assay for DSPE-PEG 2000 is not applicable as it is not a pharmacologically active compound with a specific target. Its properties are characterized by physical methods, such as dynamic light scattering (DLS) to measure particle size, and zeta potential to assess surface charge. Its ability to form micelles can be assessed in buffer solutions.
|
| Cell Assay |
Cellular experiments with DSPE-PEG 2000 typically involve evaluating the uptake and cytotoxicity of PEGylated liposomes or nanoparticles in cell lines. The compound itself is considered biologically inert and is used as a formulation component rather than an active agent. Specific protocols depend on the encapsulated drug or imaging agent.
|
| Animal Protocol |
In vivo animal experiments using DSPE-PEG 2000 typically involve the administration of liposomal or nanoparticle formulations containing the compound. For example, PEGylated liposomes loaded with a chemotherapeutic agent can be injected intravenously into tumor-bearing mice to evaluate pharmacokinetics, biodistribution, and antitumor efficacy. Specific protocols depend on the therapeutic payload.
|
| ADME/Pharmacokinetics |
DSPE-PEG 2000 is a formulation excipient and does not have conventional pharmacokinetic properties as a pharmacologically active drug. Its role is to modify the PK of encapsulated drugs by prolonging circulation time and altering biodistribution. The PEG chain provides steric stabilization, reducing opsonization and clearance.
|
| Toxicity/Toxicokinetics |
DSPE-PEG 2000 is generally considered non-toxic and is widely used in pharmaceutical formulations as an excipient. It has been used in FDA-approved liposomal drug products. As a PEGylated lipid, it is well-tolerated in vivo. However, specific toxicity data are not provided.
|
| References | |
| Additional Infomation |
DSPE-PEG 2000 (CAS: 892144-24-0) is a non-toxic and biodegradable amphiphilic copolymer used in drug delivery. It is a PEG-lipid conjugate consisting of DSPE and PEG 2000. The compound forms micelles and liposomes for drug delivery, providing a PEG coating that enhances biocompatibility and circulation time. It is not a therapeutic drug itself but a critical excipient in drug delivery systems. Its formula is (C2H4O)nC42H82NO10P.
|
| Molecular Formula |
C44H86NO11P
|
|---|---|
| Molecular Weight |
836.127516269684
|
| Exact Mass |
835.593
|
| CAS # |
892144-24-0
|
| Related CAS # |
DSPE-PEG;145035-96-7
|
| PubChem CID |
122632359
|
| Appearance |
White to off-white solid powder
|
| LogP |
14.7
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
47
|
| Heavy Atom Count |
57
|
| Complexity |
971
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
P(=O)(O)(OCCNC(=O)OCCO)OCC(COC(CCCCCCCCCCCCCCCCC)=O)OC(CCCCCCCCCCCCCCCCC)=O
|
| InChi Key |
BPZILUVAHZTEEE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C44H86NO11P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-42(47)53-39-41(40-55-57(50,51)54-37-35-45-44(49)52-38-36-46)56-43(48)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h41,46H,3-40H2,1-2H3,(H,45,49)(H,50,51)
|
| Chemical Name |
[3-[hydroxy-[2-(2-hydroxyethoxycarbonylamino)ethoxy]phosphoryl]oxy-2-octadecanoyloxypropyl] octadecanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~71.43 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1960 mL | 5.9799 mL | 11.9599 mL | |
| 5 mM | 0.2392 mL | 1.1960 mL | 2.3920 mL | |
| 10 mM | 0.1196 mL | 0.5980 mL | 1.1960 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
